Supplementary Figure S1 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S1. B3 binds to PD-L1 on multiple tumor types.</p

Supplementary Figure Legends from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

Supplementary Figure Legends from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHH

Supplementary Figure S3 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S3. Single agent treatment with B3 does not alter B16 growth in vivo.</p

Supplementary Figure S5 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S5. Combination B3-IL2 and A12-IFNγ has additive benefit over either agent alone.</p

Supplementary Figure S4 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S4. Lack of efficacy of B3-IL2 in KPC model and A12-GMCSF in Panc02 model.</p

Supplementary Figure S2 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S2. In vitro killing of IFNγ treated B16-ova cells by activated OT-I T cells is inhibited by PD-L1.</p

Supplementary Figure S6 from Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1–Specific VHHs

S6. A12-IFNγ alters the tumor microenvironment in KPC organoid model of pancreatic cancer.</p